IBAB Ion Beam Applications SA

IBA – Transparency Notification

IBA – Transparency Notification



Louvain-la-Neuve, Belgium, January 28, 2020, 17.30

Summary of the notification

IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 24, 2020.

In its notification, Norges Bank has notified, that following a disposal of IBA shares with voting rights and an acquisition of equivalent financial instruments, its total holding in IBA SA remains the same as in its previous notification but its holding in voting rights has crossed downwards the 3% threshold on January 23, 2020.

In details, on January 23, 2020, Norges Bank owned (A) 707.489 IBA shares with voting rights (versus 1.046.025 shares in its previous notification), representing 2.35 % of the total number of shares issued by IBA (30 133 920) (versus 3.47% in its previous notification), as well as (B) 701.580 equivalent financial instruments (versus 363.044 in its previous notification) representing 2.33% of the total number of shares issued by IBA (30 133 920) (versus 1.20% in its previous notification).

Content of the notification

·Reason for the notification: Acquisition or disposal of voting securities or voting rights

·Persons subject to the notification requirement: Norges Bank

·Date on which the threshold is crossed: 23/01/2020

·Threshold crossed (in %): 3%

·Denominator: 30 133 920

·Notified details: (extract of the received notification form)

           

A) Voting rightsPrevious notificationAfter the transaction 
 # of voting rights# of voting rights% of voting rights 
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities 
Norges Bank1.046.025707.489 2.35%  
 TOTAL707.48902.35%0,00% 
       
B) Equivalent financial instrumentsAfter the transaction
Holder of equivalent financial instruments Type of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
Norges BankShares on loan (right to recall) At any time701.5802.33 %physical
 TOTAL 701.5802.33 % 
       
 TOTAL (A & B)  # of voting rights%of voting rights 
    1.409.0694,68% 

·Full chain of controlled undertakings through which the holding is effectively held

Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

For further information, please contact:

IBA

Elodie Jaumain

Paralegal

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

Attachment

EN
28/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

Guy Sips ... (+2)
  • Guy Sips
  • Michiel Declercq
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: Large X-ray sterilisation solution sale Proximus: Stijn Bijnens new CEO of Proximus

 PRESS RELEASE

Steri-Tek to boost sterilization capacity of its Texas-based center fi...

Steri-Tek to boost sterilization capacity of its Texas-based center fivefold with IBA’s X-ray irradiation system Louvain-la-Neuve, Belgium, June 18, 2025 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with Steri-Tek, a growing irradiation services provider, to install a fully-integrated Be Wide X-ray Solution. IBA’s solution will be installed at Steri-Tek’s service center near Dallas-Fort Worth Metro Area, Texas, which was op...

 PRESS RELEASE

 Steri-Tek va quintupler la capacité de stérilisation de son centre au...

 Steri-Tek va quintupler la capacité de stérilisation de son centre au Texas avec un système d’irradiation par rayons X d’IBA Louvain-la-Neuve, Belgique, le 18 juin 2025 - IBA (Ion Beam Applications S.A.), le leader mondial des technologies d’accélération de particules et des solutions de pointe d'irradiation industrielle par faisceau d'électrons et rayons X, annonce aujourd'hui avoir signé un contrat avec Steri-Tek, un fournisseur de services d'irradiation en pleine croissance, pour installer une solution d’irradiation par rayons X, Be Wide, entièrement intégrée. La solution d'IBA sera ...

 PRESS RELEASE

Procès-verbal de l'Assemblée Générale Ordinaire d'IBA et résultats des...

Procès-verbal de l'Assemblée Générale Ordinaire d'IBA et résultats des votes Information réglementée Assemblée Générale Ordinaire du 11 juin 2025 Belgique, le 16 juin 2025 (17h50) – Ion Beam Applications SA (« IBA ») annonce que l’ensemble des résolutions proposées à ses actionnaires lors de l’Assemblée Générale Ordinaire tenue le 11 juin dernier ont été adoptées à l’unanimité. Parmi celles-ci figurent notamment : L’approbation des comptes annuels pour l’exercice clôturé le 31 décembre 2024 ;L’approbation de la proposition de dividende de 0,24 EUR par action.  Calendrier rel...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch